Interspecies scaling of maximum tolerated dose of anticancer drugs: Relevance to starting dose for phase I clinical trials

American Journal of Therapeutics

Volumn 8, Issue 2, 2001, Pages 109-116

  Mahmood, Iftekhar ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Woodmont Office Center II   (United States)

Author keywords

Interspecies scaling; Maximum tolerated dose; Mean life span potential; Mice LD10

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL MODEL; ARTICLE; BIOLOGICAL MODEL; DOG; DOSE RESPONSE; HUMAN; MAXIMUM TOLERATED DOSE; MOUSE; PHASE 1 CLINICAL TRIAL; PREDICTION AND FORECASTING; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MODELS, ANIMAL; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RATS; SPECIES SPECIFICITY;

EID: 0035294104     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200103000-00005     Document Type: Article

References (12)

1. Rozencwig M, Von Hoff DD, Staquet MJ, et al: Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 1981;4:21-28.
2. Penta JS, Rozencwig M, Guarino AM, et al: Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol 1979;3:97-101.
3. Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975;35:1354-1364.
4. Homan ER: Quantitative relationship between toxic doses of antitumor chemotherapeutic agents in animals and man. Cancer Chemother Rep 1972;3:13-19.
5. Paxton JW, Kim SN, Whitfield LR: Pharmacokinetic and toxicity scaling of the antitumor agents amascrine and CI-921, a new analogue in mice, rats, rabbits, dogs and humans. Cancer Res 1990;50:2692-2697.
6. Boxenbaum H, Dilea C: First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995;35:957-966.
7. Mordenti J: Dosage regimen design for pharmaceutical studies conducted in animals. J Pharm Sci 1986;75:352-357.
8. Watanabe K, Bois FY, Zeise L: Interspecies extrapolation: a reexamination of acute toxicity data. Risk Analysis 1992;12:301-309.
9. Rhomberg LR, Wolff SK: Empirical scaling of single oral lethal doses across mammalian species based on large data base. Risk Analysis 1998;18:741-753.
10. Mahmood I, Balian JD: Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996;85:411-414.
11. Mahmood I, Balian JD: Interspecies scaling: predicting clearance of drugs n humans. Three different approaches. Xenobiotica 1996;26:887-895.
12. Sacher G. Relation of lifespan to brain weight and body weight in mammals. In: CIBA Foundation Colloquia on Aging. (Eds. Wolstenholme GEW, O'Connor M). Churchill, London, 1959,pp115-133.